What Caught Our Attention in the Investment World? – Week of September 9-13, 2019
By Kuldip K. Ambastha and Anil K. Ambastha Acadia Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company which has Nuplazid (aka: pimavanserin) in its product pipeline. Nuplazid has been used by individuals suffering from Parkinson’s disease-linked psychosis. Acadia has now analyzed Nuplazid in relation to individuals suffering from dementia-related psychosis. Currently, no approved drugs exist in …
Continue reading “What Caught Our Attention in the Investment World? – Week of September 9-13, 2019”